FGL2 and mycosis fungoides: After having been initially reported to be increased in various types of solid tumors, FGL-2 protein has been tested as a potential biomarker for early MF diagnosis by studying its activity in peripheral blood mononuclear cells of MF patients and comparing the results with those observed in patients with inflammatory dermatoses.